Product Name: LATS1-CT
Product Number: AB-NK091-2
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Large tumour suppressor 1 protein-serine kinase (WARTS)
Target Alias: Large tumour suppressor 1; LATS, large tumour suppressor, 1; WARTS; wts; ENSG00000131023
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK091-2
Antibody Target Type: Pan-specific
Protein UniProt: O95835
Protein SigNET: O95835
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human LATS1 sequence peptide Cat. No.: PE-01BDM99
Antibody Immunogen Sequence: CGSEQQSDEDDQNTGSEIKN
Target Alias: Large tumour suppressor 1; LATS, large tumour suppressor, 1; WARTS; wts; ENSG00000131023
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK091-2
Antibody Target Type: Pan-specific
Protein UniProt: O95835
Protein SigNET: O95835
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human LATS1 sequence peptide Cat. No.: PE-01BDM99
Antibody Immunogen Sequence: CGSEQQSDEDDQNTGSEIKN
Antibody Immunogen Description: Corresponds to amino acid residues G1106 to N1124; C-terminus
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 140-170 kDa.
Related Product 1: LATS1-CT blocking peptide
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 140-170 kDa.
Related Product 1: LATS1-CT blocking peptide
Related Product 2: LATS1-pS464 phosphosite-specific antibody (Cat. No.: AB-PK677)
Related Product 3: LATS1-pS909 phosphosite-specific antibody (Cat. No.: AB-PK678)
Related Product 4: LATSSubtide - LATS2 (KPM) protein kinase substrate peptide
Related Product 3: LATS1-pS909 phosphosite-specific antibody (Cat. No.: AB-PK678)
Related Product 4: LATSSubtide - LATS2 (KPM) protein kinase substrate peptide
Scientific Background: LATS1 (WARTS) is a protein-serine/threonine kinase of the AGC group and NDR family. LATS1 appears to be a tumour suppressor protein (TSP), although it undergoes a typical rate of bystander mutations in human cancers. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It also promotes apoptosis by activating the transcription of BAX, caspase 3 and p53, and inhibiting the oncogene actions of YAP1. It can phosphorylate and inactivate the YAP1 and inhibit its translocation to the nucleus for transcription of genes important for proliferation and migration. NUAK1 and NUAK2 mediated phosphorylation of LATS1 can be inhibited with a LATS1 mutation of S464A. Inhibition of LATS1-YAP1 interaction can occur with a Y559F mutation. The K734A mutation can abrogate kinase phosphotransferase activity, lack of p53 translation, increased time for mitosis, autophosphorylation, and increased ploidy. LATS1 also negatively regulates the G2/M transition by downregulating CDK1 phosphotransferase activity. M669I and R806P mutations have been associated with lung adenocarcinoma and lung large cell carcinoma, respectively. Decreased LATS1 expression due to hypermethylation of the promoter have been associated with breast cancer, acute lymphoblastic leukemia, ovarian cancer, and astrocytoma. However, the very low frequency of reported somatic mutations in this protein indicates that it may function as a tumour requiring protein (TRP) in many human tumours. LATS1 is activated by phosphorylation at S909 and T1079.
© Kinexus Bioinformatics Corporation 2017